Back

TRISCEND II trial: TTVR outcomes by baseline TR severity

29 August 2025 (11:15 - 11:30)
Organised by: Logo
Congress Presentation Part of: Late Breaking Clinical Science: advances in valvular heart disease Tricuspid Valve Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Philipp Lurz

University Medical Centre of the Johannes Gutenberg University, Mainz (Germany)

3 More presentations in this session

Presentation thumbnail
LAA-CLOSURE - Prophylactic surgical closure of the LAA in SAVR
Professor T. Kiviniemi (Turku, FI)
Slides Video
Presentation thumbnail
VANTAGE-30-Day and 1-Year Outcomes
Professor N. van Mieghem (Genk, BE)
Slides Video
Presentation thumbnail
AI-based quantification of mitral regurgitation with 3D TOE
Doctor C. Guarino (Badalona, ES)
Slides Video

Access the full session

Session thumbnail
Late Breaking Clinical Science: advances in valvular heart disease
Video

The Event

Event poster

ESC Congress 2025

29 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Interventional treatment
17 May 2025
thumbnail
Congress Presentation
The impact of baseline right heart size and function on heart failure hospitalization and mortality: 2-year results of the TRILUMINATE Trial
31 August 2025
thumbnail
Congress Session
Young Investigator Award Session in Valvular Heart Disease
1 September 2024
thumbnail
Congress Presentation
A randomised trial of transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation: TRISCEND II trial
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources